San Antonio, TX (PRWEB) September 13, 2012: Conflicting information is circulating about two more possible deaths in patients enrolled in a clinical trial for Bristol-Myers Squibb’s experimental Hepatitis C drug, BMS-986094.
The clinical trial for BMS-986094 was halted in August after one patient died and several others reported suffering heart injuries. Bristol-Myers Squibb discontinued development of BMS-986094 altogether after receiving reports of eight other patient hospitalizations, the Wall Street Journal recently reported. Injuries reported in trial patients include:
- Heart valve damage
- Heart attacks and heart failure
- Kidney damage
- Abnormal heart rhythms
- Fatal heart damage
More patients are coming forward each day to report injuries associated with the trials. Thomas J. Henry, a national trial firm, is investigating a number of these claims and has already filed a lawsuit on behalf of one of the victims.
“We have already interviewed a number of injury victims from the Hepatitis C trials,” Thomas J. Henry said. “We are actively investigating and litigating these matters.”
According to Clinicaltrials.gov, an estimated 360 patients were enrolled in the clinical trials. Bristol-Myers Squibb is currently monitoring more than 100 patients who took part in the halted trial and is notifying 150 patients who were part of earlier trials, according to the Wall Street Journal. The Hepatitis C trials took place in various medical facilities across the country, including cities in Texas, Arizona, California, Colorado, Georgia, Missouri, and New York.
The Law Offices of Thomas J. Henry